These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

43 related articles for article (PubMed ID: 12034047)

  • 1. Dynamics of hepatitis C virus monitored by real-time quantitative polymerase chain reaction during first 2 weeks of IFN-beta treatment are predictive of long-term therapeutic response.
    Enomoto M; Nishiguchi S; Tanaka M; Fukuda K; Ueda T; Tamori A; Habu D; Takeda T; Shiomi S; Yano Y; Otani S
    J Interferon Cytokine Res; 2002 Mar; 22(3):389-95. PubMed ID: 12034047
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Changes in serum levels of hepatitis C virus genotype 1b monitored by real-time quantitative polymerase chain reaction as a predictor of long term response to interferon-alpha treatment.
    Enomoto M; Nishiguchi S; Shiomi S; Tanaka M; Yokogawa T; Fukuda K; Ueda T; Tamori A; Habu D; Takeda T; Yano Y; Otani S
    Am J Gastroenterol; 2002 Feb; 97(2):420-6. PubMed ID: 11866282
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A potent antiviral effect on hepatitis C viral dynamics in serum and peripheral blood mononuclear cells during combination therapy with high-dose daily interferon alfa plus ribavirin and intravenous twice-daily treatment with interferon beta.
    Asahina Y; Izumi N; Uchihara M; Noguchi O; Tsuchiya K; Hamano K; Kanazawa N; Itakura J; Miyake S; Sakai T
    Hepatology; 2001 Aug; 34(2):377-84. PubMed ID: 11481623
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of molecular parameters for routine assessment of viremia in patients with chronic hepatitis C who are undergoing antiviral therapy.
    Kessler HH; Pierer K; Santner BI; Vellimedu SK; Stelzl E; Marth E; Fickert P; Stauber RE
    J Hum Virol; 1998; 1(5):314-9. PubMed ID: 10195258
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interferon treatment for patients with chronic hepatitis C infected with high viral load of genotype 2 virus.
    Nakamura H; Ogawa H; Kuroda T; Yamamoto M; Enomoto H; Kishima Y; Yoshida K; Ito H; Matsuda M; Noguchi S
    Hepatogastroenterology; 2002; 49(47):1373-6. PubMed ID: 12239945
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Kinetics of the hepatitis C virus during interferon therapy as a marker of therapeutic response.
    Nakamuta M; Fukutomi T; Shimohashi N; Kinukawa N; Uchimura K; Tada S; Motomura K; Enjoji M; Kato M; Iwamoto H; Tanabe Y; Imari Y; Sakamoto S; Sakai H; Nawata H
    J Gastroenterol Hepatol; 2001 Jan; 16(1):29-33. PubMed ID: 11206312
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A pilot study of combination therapy with initial high-dose interferon and amantadine hydrochloride for patients with chronic hepatitis C with the genotype 1b virus.
    Uyama H; Enomoto H; Kishima Y; Yamamoto M; Yoshida K; Okuda Y; Hirotani T; Kuroda T; Ito H; Matsuda M; Terabayashi M; Noguchi S; Kawase I; Nakamura H
    Hepatogastroenterology; 2003; 50(54):2112-6. PubMed ID: 14696476
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictors of the efficacy of intravenous natural interferon-beta treatment in chronic hepatitis C.
    Fukutomi T; Fukutomi M; Iwao M; Watanabe H; Tanabe Y; Hiroshige K; Kinukawa N; Nakamuta M; Nawata H
    Med Sci Monit; 2000; 6(4):692-8. PubMed ID: 11208393
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Different viral kinetics between hepatitis C virus genotype 1 and 2 as on-treatment predictors of response to a 24-week course of high-dose interferon-alpha plus ribavirin combination therapy.
    Yu ML; Chuang WL; Dai CY; Lee LP; Hsieh MY; Lin ZY; Chen SC; Hsieh MY; Wang LY; Chang WY; Tsai SL; Kuo HT
    Transl Res; 2006 Sep; 148(3):120-7. PubMed ID: 16938649
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Early loss of serum hepatitis C virus RNA can predict a sustained response to interferon therapy in patients with chronic hepatitis C.
    Karino Y; Toyota J; Sugawara M; Higashino K; Sato T; Ohmura T; Suga T; Okuuchi Y; Matsushima T
    Am J Gastroenterol; 1997 Jan; 92(1):61-5. PubMed ID: 8995939
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Early prediction of hepatitis C virus (HCV) infection relapse in nonresponders to primary interferon therapy by means of HCV RNA whole-blood analysis.
    Watkins-Riedel T; Ferenci P; Steindl-Munda P; Gschwantler M; Mueller C; Woegerbauer M
    Clin Infect Dis; 2004 Dec; 39(12):1754-60. PubMed ID: 15578395
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interferon-alpha and ribavirin treatment in patients with hepatitis C virus-related systemic vasculitis.
    Cacoub P; Lidove O; Maisonobe T; Duhaut P; Thibault V; Ghillani P; Myers RP; Leger JM; Servan J; Piette JC
    Arthritis Rheum; 2002 Dec; 46(12):3317-26. PubMed ID: 12483738
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pilot study on the safety and efficacy of intravenous natural beta-interferon therapy in patients with chronic hepatitis C unresponsive to alpha-interferon.
    Mazzoran L; Grassi G; Giacca M; Gerini U; Baracetti S; Fanni-Canelles M; Zorat F; Pozzato G
    Ital J Gastroenterol Hepatol; 1997 Aug; 29(4):338-42. PubMed ID: 9476188
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Complete eradication of hepatitis C virus after interferon treatment for chronic hepatitis C.
    De Mitri MS; Morsica G; Chen CH; Mele L; Baccarini P; Chianese R; Piccinini A; Lazzarin A; Pisi E
    Ital J Gastroenterol Hepatol; 1997 Jun; 29(3):255-61. PubMed ID: 9646218
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination therapy with interferon alpha and beta to chronic hepatitis C.
    Horiike N; Hino H; Tanaka Y; Miyaoka H; Miki S; Yamashita S; Matsuura B; Kubo Y; Ikeda Y; Akbar SM; Masumoto T; Michitaka K; Onji M
    Oncol Rep; 2003; 10(1):157-61. PubMed ID: 12469163
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of in vitro interferon-beta administration on hepatitis C virus in peripheral blood mononuclear cells as a predictive marker of clinical response to interferon treatment for chronic hepatitis C.
    Mochizuki K; Kagawa T; Takashimizu S; Kawazoe K; Kojima S; Nagata N; Nakano A; Nishizaki Y; Shiraishi K; Itakura M; Watanabe N; Mine T; Matsuzaki S
    World J Gastroenterol; 2004 Mar; 10(5):733-6. PubMed ID: 14991949
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Early clearance of circulating hepatitis C virus enhanced by induction therapy with twice-a-day intravenous injection of IFN-beta.
    Ikeda F; Shimomura H; Miyake M; Fujioka SI; Itoh M; Takahashi A; Iwasaki Y; Sakaguchi K; Yamamoto K; Higashi T; Tsuji T
    J Interferon Cytokine Res; 2000 Sep; 20(9):831-6. PubMed ID: 11032403
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Different hepatitis C virus dynamics of free-virions and immune-complexes after initiation of interferon-alpha in patients with chronic hepatitis C.
    Fujita N; Kaito M; Takeo M; Horiike S; Tanaka H; Ikoma J; Watanabe S; Adachi Y
    J Hepatol; 2003 Dec; 39(6):1013-9. PubMed ID: 14642620
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nonimmune complexed HCV RNA titer in serum as a predictor of interferon response in patients with chronic hepatitis C.
    Fujita N; Kaito M; Takeo M; Iwasa M; Ikoma J; Watanabe S; Adachi Y
    Am J Gastroenterol; 2003 Mar; 98(3):645-52. PubMed ID: 12650801
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Possible mechanisms of elevation of serum transaminase levels during interferon-beta therapy in chronic hepatitis C patients.
    Fujimori K; Mochida S; Matsui A; Ohno A; Fujiwara K
    J Gastroenterol; 2002 Jan; 37(1):40-6. PubMed ID: 11824799
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.